Characterization and pharmacokinetic study of recombinant human N-acetylgalactosamine-6-sulfate sulfatase

Molecular Genetics and Metabolism

Volumn 91, Issue 1, 2007, Pages 69-78

  Tomatsu, Shunji ^a   Montaño, Adriana M ^a   Gutierrez, Monica ^a   Grubb, Jeffrey H ^a   Oikawa, Hirotaka ^a   Dung, Vu Chi ^a   Ohashi, Amiko ^a   Nishioka, Tatsuo ^a   Yamada, Masamichi ^b   Yamada, Mana ^b   Tosaka, Yasuhiro ^b   Trandafirescu, Georgeta G ^a   Orii, Tadao ^c  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JCR Phamaceuticals   (Japan)

^c GIFU UNIVERSITY   (Japan)

Author keywords

Chinese hamster ovary cell; Enzyme replacement therapy; GALNS; Lysosomal storage disease; Mucopolysaccharidosis IVA

Indexed keywords

FLUORESCENT DYE; MANNOSE 6 PHOSPHATE; N ACETYLGALACTOSAMINE 6 SULFATASE; RECOMBINANT PROTEIN;

AFFINITY CHROMATOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CARTILAGE CELL; CIRCULATION; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INHIBITION; DRUG UPTAKE; ENZYME PURIFICATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VIVO STUDY; MORQUIO SYNDROME; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; PROTEIN FOLDING; SINGLE DRUG DOSE; WESTERN BLOTTING;

ANIMALS; CHO CELLS; CHONDROITINSULFATASES; CRICETINAE; CRICETULUS; DISEASE MODELS, ANIMAL; ENZYME STABILITY; HUMANS; MICE; MICE, KNOCKOUT; MICE, TRANSGENIC; MUCOPOLYSACCHARIDOSIS IV; RECOMBINANT PROTEINS; TIME FACTORS; TISSUE DISTRIBUTION;

CRICETULUS GRISEUS; IVA; MUS;

EID: 34147098050     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2007.01.004     Document Type: Article

References (40)

1. Neufeld E.F., and Muenzer J. The Mucopolysaccharidoses. In: Scriver C.R., Beaudet A.L., Sly W.S., and Valle D. (Eds). The Metabolic and Molecular Bases of Inherited Disease. eighth ed. (2001), McGraw-Hill, New York 3421-3452
2. Northover H., Cowie R.A., and Wraith J.E. Mucopolysaccharidosis type IVA (Morquio syndrome): a clinical review. J. Inherit. Metab. Dis. 19 (1996) 357-365
3. McClure J., Smith P.S., Sorby-Adams G., and Hopwood J.J. The histological and ultrastructural features of the epiphyseal plate in Morquio type A syndrome (mucopolysaccharidosis type IVA). Pathology 18 (1986) 217-221
4. -/-) produced by targeted disruption of the gene defective in Morquio A disease. Hum. Mol. Genet. 12 (2003) 3349-3358
5. tm(hC79S•mC76S)slu) tolerant to human N-acetylgalactosamine-6-sulfate sulfatase. Hum. Mol. Genet. 14 (2005) 3321-3335
6. Bielicki J., Fuller M., Guo X.H., Morri C.P., Hopwood J.J., and Anson D.S. Expression, purification and characterization of recombinant human N-acetylgalactosamine-6-sulphatase. Biochem. J. 311 Pt 1 (1995) 333-339
7. Tomatsu S., Fukuda S., Masue M., Sukegawa K., Fukao T., Yamagishi A., Hori T., Iwata H., Ogawa T., Nakashima Y., et al. Morquio disease: isolation, characterization and expression of full-length cDNA for human N-acetylgalactosamine-6-sulfate sulfatase. Biochem. Biophys. Res. Commun. 181 (1991) 677-683
8. Masue M., Sukegawa K., Orii T., and Hashimoto T. N-acetylgalactosamine-6-sulfate sulfatase in human placenta: purification and characteristics. J. Biochem. (Tokyo) 110 (1991) 965-970
9. Dahms N.M., Lobel P., and Kornfeld S. Mannose 6-phosphate receptors and lysosomal enzyme targeting. J. Biol. Chem. 264 (1989) 12115-12118
10. Kornfeld S., and Mellman I. The biogenesis of lysosomes. Annu. Rev. Cell Biol. 5 (1989) 483-525
11. Barton N.W., Brady R.O., Dambrosia J.M., Di Bisceglie A.M., Doppelt S.H., Hill S.C., Mankin H.J., Murray G.J., Parker R.I., and Argoff C.E. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N. Engl. J. Med. 324 (1991) 464-470
12. Barranger J.A., and O'Rourke E. Lessons learned from the development of enzyme therapy for Gaucher disease. J. Inherit. Metab. Dis. Suppl. 2 (2001) 89-96
13. Brady R.O., and Schiffmann R. Clinical features of and recent advances in therapy for Fabry disease. JAMA 284 (2000) 2771-2775
14. Schiffmann R., Murray G.J., Treco D., Daniel P., Sellos-Moura M., Myers M., Quirk J.M., Zirzow G.C., Borowski M., Loveday K., Anderson T., Gillespie F., Oliver K.L., Jeffries N.O., Doo E.T., Liang J., Kreps C., Gunter K., Frei K., Crutchfield K., Selden R.F., and Brady R.O. Infusion of -galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc. Natl. Acad. Sci. USA 97 (2000) 365-370
15. Kakkis E.D., Muenzer J., Tiller G.E., Waber L., Belmont J., Passage M., Izykowski B., Phillips J., Doroshow R., Walot I., Hoft R., and Neufeld E.F. Enzyme-replacement therapy in mucopolysaccharidosis I. N. Engl. J. Med. 344 (2001) 182-188
16. Muenzer J., Lamsa J.C., Garcia A., Dacosta J., Garcia J., and Treco D.A. Enzyme replacement therapy in mucopolysaccharidosis type II (Hunter syndrome): a preliminary report. Acta Paediatr Suppl. 91 (2002) 98-99
17. Harmatz P., Ketteridge D., Giugliani R., Guffon N., Teles E.L., Miranda M.C., Yu Z.F., Swiedler S.J., and Hopwood J.J. MPS VI Study Group. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics 115 (2005) e681-e689
18. Harmatz P., Whitley C.B., Waber L., Pais R., Steiner R., Plecko B., Kaplan P., Simon J., Butensky E., and Hopwood J.J. Enzyme replacement therapy in mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). J. Pediatr. 144 (2004) 574-580
19. Harmatz P., Giugliani R., Schwartz I., Guffon N., Teles E.L., Miranda M.C., Wraith J.E., Beck M., Arash L., Scarpa M., Yu Z.F., Wittes J., Berger K.I., Newman M.S., Lowe A.M., Kakkis E., and Swiedler S.J. MPS VI Phase 3 Study Group. Enzyme replacement therapy for mucopolysaccharidosis VI: A phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J. Pediatr. 148 (2006) 533e
20. Vogler C., Levy B., Galvin N.J., Thorpe C., Sands M.S., Barker J.E., Baty J., Birkenmeier E.H., and Sly W.S. Enzyme replacement in murine mucopolysaccharidosis type VII: neuronal and glial response to beta-glucuronidase requires early initiation of enzyme replacement therapy. Pediatr. Res. 45 (1999) 838-844
21. Vogler C., Sands M.S., Levy B., Galvin N., Birkenmeier E.H., and Sly W.S. Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival. Pediatr. Res. 39 (1996) 1050-1054
22. Sands M.S., Vogler C., Kyle J.W., Grubb J.H., Levy B., Galvin N., Sly W.S., and Birkenmeier E.H. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J. Clin. Invest. 93 (1994) 2324-2331
23. Crawley A.C., Brooks D.A., Muller V.J., Petersen B.A., Isaac E.L., Bielicki J., King B.M., Boulter C.D., Moore A.J., Fazzalari N.L., Anson D.S., Byers S., and Hopwood J.J. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J. Clin. Invest. 97 (1996) 1864-1873
24. Crawley A.C., Niedzielski K.H., Isaac E.L., Davey R.C., Byers S., and Hopwood J.J. Enzyme replacement therapy from birth in a feline model of mucopolysaccharidosis type VI. J. Clin. Invest. 99 (1997) 651-662
25. Brooks D.A., King B.M., Crawley A.C., Byers S., and Hopwood J.J. Enzyme replacement therapy in Mucopolysaccharidosis VI: evidence for immune responses and altered efficacy of treatment in animal models. Biochim. Biophys. Acta 1361 (1997) 203-216
26. Kakkis E.D., McEntee M.F., Schmidtchen A., Neufeld E.F., Ward D.A., Gompf R.E., Kania S., Bedolla C., Chien S.L., and Shull R.M. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem. Mol. Med. 58 (1996) 156-167
27. Niwa H., Yamamura K., and Miyazaki J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene 108 (1991) 193-199
28. van Diggelen O.P., Zhao H., Kleijer W.J., Janse H.C., Poorthuis B.J., van Pelt J., Kamerling J.P., and Galjaard H. A fluorimetric enzyme assay for the diagnosis of Morquio disease type A (MPS IV A). Clin. Chim. Acta 187 (1990) 131-139
29. Peterson G.L. Review of the Folin phenol protein quantitation method of Lowry, Rosebrough, Farr and Randall. Anal. Biochem. 100 (1979) 201-220
30. Toietta G., Severini G.M., Traversari C., Tomatsu S., Sukegawa K., Fukuda S., Kondo N., Tortora P., and Bordignon C. Various cells retrovirally transduced with N-acetylgalactosoamine-6-sulfate sulfatase correct Morquio skin fibroblasts in vitro. Hum. Gene Ther. 12 (2001) 2007-2016
31. Shull R.M., Kakkis E.D., McEntee M.F., Kania S.A., Jonas A.J., and Neufeld E.F. Enzyme replacement in a canine model of Hurler syndrome. Proc. Natl. Acad. Sci. USA 91 (1994) 12937-12941
32. Vogler C., Levy B., Grubb J.H., Galvin N., Tan Y., Kakkis E., Pavloff N., and Sly W.S. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc. Natl. Acad. Sci. USA 102 (2005) 14777-14782
33. Sands M.S., Vogler C.A., Ohlemiller K.K., Roberts M.S., Grubb J.H., Levy B., and Sly W.S. Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII. J. Biol. Chem. 276 (2001) 43160-43165
34. Ioannou Y.A., Zeidner K.M., Gordon R.E., and Desnick R.J. Fabry disease: preclinical studies demonstrate the effectiveness of alpha-galactosidase A replacement in enzyme-deficient mice. Am. J. Hum. Genet. 1 (2001) 14-25
35. Dunder U., Kaartinen V., Valtonen P., Vaananen E., Kosma V.M., Heisterkamp N., Groffen J., and Mononen I. Enzyme replacement therapy in a mouse model of aspartylglycosaminuria. FASEB J. 14 (2000) 361-367
36. Yu W.H., Zhao K.W., Ryazantsev S., Rozengurt N., and Neufeld E.F. Short-term enzyme replacement in the murine model of Sanfilippo syndrome type B. Mol. Genet. Metab. 71 (2000) 573-580
37. Byers S., Crawley A.C., Brumfield L.K., Nuttall J.D., and Hopwood J.J. Enzyme replacement therapy in a feline model of MPS VI: modification of enzyme structure and dose frequency. Pediatr. Res. 47 (2000) 743-749
38. Landgrebe J., Dierks T., Schmidt B., and von Figura K. The human SUMF1 gene, required for posttranslational sulfatase modification, defines a new gene family which is conserved from pro- to eukaryotes. Gene 316 (2003) 47-56
39. Cosma M.P., Pepe S., Annunziata I., Newbold R.F., Grompe M., Parenti G., and Ballabio A. The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell 113 (2003) 445-456
40. Nishioka T., Tomatsu S., Montano A.M., Trandafirescu G.G., Lopez P., Grubb J., Kanai R., Kobayashi H., Yamaguchi S., Gottesman G.S., Cahill R., Noguchi A., Miyamoto K., and Sly W.S. Targeted drug delivery to bone: characterization of human tissue-nonspecific alkaline phosphatase tagged with an acidic oligopeptide. Mol. Genet. Metab. 88 (2006) 244-255